Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04767074
Other study ID # 20-005-WP
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2020
Est. completion date December 2024

Study information

Verified date April 2024
Source West Park Healthcare Centre
Contact Ana Oliveira, PhD
Phone 6477651525
Email ana.oliveira@westpark.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Coughing affects almost all individuals with ILD leading to physical, psychological and social distress and prevents individuals from performing their activities of daily living, working or socialising in public places. Unfortunately, there are no licensed medications available to treat chronic cough and the few drugs that have been tried resulted in little efficacy and significant side effects. Drug-free cough control interventions have shown promise in reducing the severity and impact of coughing on patients' lives but have not been tested in individuals with ILD. This study aims to explore the feasibility and effectiveness of a non-pharmacological cough control therapy, as an adjuvant of pulmonary rehabilitation, in patients with ILD and chronic cough (>8 weeks in duration).


Description:

Research questions and hypotheses i) Is a non-pharmacological cough control therapy feasible to treat chronic cough in patients with ILD? Hypothesis: Given the results of previous non-pharmacological interventions in patients with refractory cough, we predict that this intervention will be feasible and well accepted in patients with ILD. ii) Is a non-pharmacological cough control therapy more effective than pulmonary rehabilitation (PR) alone to treat chronic cough in patients with ILD? Hypotheses: Given the results of previous non-pharmacological interventions in patients with refractory cough, we predict that improvements observed in participants receiving the non-pharmacological intervention will exceed those receiving PR alone. Improvements are expected in HRQOL (exceeding the minimal clinically important difference), intensity of cough-related sensations and symptoms of fatigue. Research Design The proposed research is a feasibility pre-post intervention study. Study details: Adults with ILD and chronic cough will be enrolled in this study. Potential eligible patients will be recruited from the outpatient PR program at West Park Healthcare Centre and St. Joseph's Healthcare. As the outpatient pulmonary rehabilitation program at West Park Healthcare Center and St. Joseph's Healthcare will transition partially to virtual meetings, the interactions between the research team and patients will be completed via phone calls or online. This research study will be delivered online using the Zoom Healthcare Plan, an online platform that is available at West Park Healthcare Centre, and is used for telerehabilitation programs. Participants will be enrolled into a PR program composed of aerobic and strengthening exercises, disease-specific education and self-management, as part of their usual care. Two weeks before termination of PR, participants will start the non-pharmacological cough control therapy, following the intervention proposed by Chamberlain colleagues (2017). Participants will attend four virtual sessions of 45 to 60 minutes of educational and self-management This study will measure several clinical outcomes. 1. Feasibility will be reflected by the number of eligible patients enrolling (enrolment rate of at least 75%) and completing the intervention (attendance rate of at least 80%), compliance with the sessions and adverse events. 2. Leicester cough questionnaire 3. The King's Brief Interstitial Lung Disease (KBILD) 4. Modified Borg scale (mBorg 5. Cough Hypersensitivity Questionnaire (CHQ) 6. Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-F) 7. Global rating of change questionnaire (GRCQ) 8. Satisfaction Semi-structured interviews using open-ended questions will be conducted before and after the cough control intervention to capture participants' expectations and perspectives about the cough control therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Individuals will be included if having confirmed diagnosis of any ILD by a physician (as per Canadian Thoracic Society's guideline for evaluating patients with fibrotic interstitial lung disease) and a chronic cough lasting more than 8 weeks in duration Exclusion Criteria: - self-reports of moderate or large sputum production - effective or suspected exacerbation of the respiratory condition in the past month - upper respiratory tract infection in the past month - use of angiotensin-converting enzyme inhibitor medication - changes in the prescribed medication in the previous month - evidence of traction bronchiectasis in the HRCT - evidence of other medical conditions that prevent performance of an exercise training program - unable to read or speak in English / unable to provide informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Non-pharmacological Cough control Therapy
Participants will attend four virtual sessions of 45 to 60 minutes of educational and self-management. Session 1 General assessment Prescription and taught of one cough suppression technique. Session 2 Cough principles: mechanism, cough reflex, chronic cough, the importance of cough and negative effects of repeated coughing. Cough control: identify triggers, use cough suppressions and distractions techniques. Session 3 Breathing pattern retraining and laryngeal hygiene: reinforce nasal breathing and pursed lips breathing as strategies to avoid the urge to cough, identification of risk factors for laryngeal dehydration and hydration education. Session 4 Reinforcement: Clarification of doubts, techniques' reinforcement and application during daily life situations.

Locations

Country Name City State
Canada St. Joseph's Healthcare Hamilton Hamilton Ontario
Canada West Park Healthcare Centre Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
West Park Healthcare Centre St. Joseph's Healthcare Hamilton

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Chamberlain Mitchell SA, Garrod R, Clark L, Douiri A, Parker SM, Ellis J, Fowler SJ, Ludlow S, Hull JH, Chung KF, Lee KK, Bellas H, Pandyan A, Birring SS. Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial. Thorax. 2017 Feb;72(2):129-136. doi: 10.1136/thoraxjnl-2016-208843. Epub 2016 Sep 28. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of intervention intervention feasibility will be reflected by the number of eligible patients enrolling (enrolment rate of at least 75%) and completing the intervention (attendance rate of at least 80%), compliance with the sessions and adverse events. through study completion, average 1 year
Secondary Leicester cough questionnaire The LCQ is a validated 19-item cough-specific HRQoL questionnaire. It is divided into 3 domains (physical, social and psychological) and the overall score range from 3 to 21, with a higher score indicating a better cough related HRQOL. through study completion, average 1 year
Secondary The King's Brief Interstitial Lung Disease (KBILD) The KBILD is a self-completed health status questionnaire that comprises of 15 items with the following three domains: psychological, breathlessness and activities and chest symptoms. Total score ranges from 0 to 100; 100 representing the best health status. This KBILD has an established minimal clinically important difference of 5-points in people with ILD. through study completion, average 1 year
Secondary Modified Borg scale (mBorg) The modified Borg scale is widely used to assess the intensity of dyspnoea in individuals with chronic respiratory diseases and has recently been successfully adopted to assess the urge to cough and severity of cough in this population. The mBorg is measured on a 10 point scale; with 0 as feelings of "nothing at all" (no signs of dyspnoea) to 10 as "very very hard" intensity of dyspnoea. through study completion, average 1 year
Secondary Cough Hypersensitivity Questionnaire (CHQ) The presence of triggers and laryngeal symptoms associated with cough were recorded using a standardized novel questionnaire, the CHQ. The CHQ comprises 23 items related to cough triggers, urge and laryngeal sensations associated with cough. through study completion, average 1 year
Secondary Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-F) The FACIT-F is, a multi-dimensional 13-item questionnaire assessing tiredness, weakness and difficulty in handling daily living activities due to fatigue, over the previous 7 days. Participants are asked to rate their level of fatigue on a 4-point scale, where 0-not very much to 4- very much so. The sum of these values will provide a FACIT-F score ranging 0 to 52 (less fatigue to most fatigue). through study completion, average 1 year
Secondary Global rating of change questionnaire (GRCQ) The GRCQ is a 15-point scale widely used to determine the participants' and health. professionals' perceptions about cough changes after interventions. Participants will be asked to rate global changes in cough in a scale ranging from -7 (a great deal worse) to +7 (a great deal better). through study completion, average 1 year
Secondary Satisfaction of cough therapy program Participants' satisfaction and perceived benefits will be evaluated following completion of the intervention participants with a 9-item survey previously used to assess interventions in chronic respiratory diseases. The survey asks participants to report their level of agreement with statements on enjoyment and perceived improvements/benefits according to a 5-point Likert type scale (1=strongly agree; 5=strongly disagree). through study completion, average 1 year
See also
  Status Clinical Trial Phase
Completed NCT00116337 - Spinal Cord Stimulation to Restore Cough N/A
Not yet recruiting NCT04064333 - Slow-Stream Expiratory Muscle Strength Training for Veterans With Dysphagia Living in Long-term Care N/A
Recruiting NCT02482818 - Efficacy of Pregabalin on Chronic Cough Phase 1/Phase 2
Terminated NCT02269761 - Chest Ultrasound of ER Patients With Cough or SOB
Active, not recruiting NCT02065440 - The Effect of Ebastine/Pseudoephedrine on Subacute Cough N/A
Completed NCT01071161 - The Effect of Azithromycin in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Productive Cough Phase 3
Completed NCT00353951 - An Observational Study of Cough / Lower Respiratory Tract Infection (LRTI) in Primary Care N/A
Terminated NCT00668317 - Bronchial Hyper-responsiveness in Reflux Cough Phase 3
Completed NCT00287339 - The Utility of Nexium in Chronic Cough and Reflux Disease Phase 4
Completed NCT00127686 - Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep Phase 1
Recruiting NCT05115097 - AI Evaluation of COVID-19 Sounds (AI-EChOS)
Recruiting NCT04457011 - Efficacy and Safety of Susu Zhike Granules for Treating Acute Cough Due to Common Cold With Cold-cough Syndrome in Children Phase 2
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Recruiting NCT03922373 - A Study of Benzonatate Soft Capsule in Chinese Healthy Subjects Phase 1
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Recruiting NCT05570539 - Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation Phase 1
Completed NCT03999203 - A Cross-sectional Study to Measure Cough in Severe Asthma N/A
Active, not recruiting NCT05479929 - Work of Breathing Assessment in Triage Scale
Recruiting NCT02495571 - Assessment of Voluntary and Reflex Cough in Patients With ALS N/A
Completed NCT02572375 - Codeine Phosphate/Guaifenesin ER Tablet 30 mg/600 mg Steady State Clinical Study Phase 1